Katherine McJunkin

Katherine McJunkin

Auto-generated profile, based on publicly available information

Katherine McJunkin

National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Program, Bethesda, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Pascal PineauPascal Pineau
Pascal Pineau
Stefano VoliniaStefano Volinia
Stefano Volinia
KMKatherine McJunkin
Katherine McJunkin
AMAgnès Marchio
Agnès Marchio
CBCarlo Battiston
Carlo Battiston
ADAnne Dejean
Anne Dejean
MicroRNA (miRNAs) are negative regulators of gene expression and can function as tumor suppressors or oncogenes. Expression patterns of miRNAs and their role in the pathogenesis of hepatocellular carcinoma (HCC) are still poorly understood. We profiled miRNA expression in tissue samples (104 HCC, 90 adjacent cirrhotic livers, 21 normal livers) as well as in 35 HCC cell lines. A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC. miR-221/222, the most up-regulated miRNAs in tumor samples, are shown to target the CDK inhibitor p27 and to enhance cell growth in vitro. Conversely, these activities can be efficiently inhibited by an antagomiR specific for miR-221. In addition, we show, using a mouse model of liver cancer, that miR-221 overexpression stimulates growth of tumorigenic murine hepatic progenitor cells. Finally, we identified DNA damage-inducible transcript 4 (DDIT4), a modulator of mTOR pathway, as a bona fide target of miR-221. Taken together, these data reveal an important contribution for miR-221 in hepatocarcinogenesis and suggest a role for DDIT4 dysregulation in this process. Thus, the use of synthetic inhibitors of miR-221 may prove to be a promising approach to liver cancer treatment.

28 February 2010 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KMKonstantinos J. Mavrakis
Konstantinos J. Mavrakis
AWAndrew L. Wolfe
Andrew L. Wolfe
EOElisa Oricchio
Elisa Oricchio
TPTeresa Palomero
Teresa Palomero
KKKim De Keersmaecker
Kim De Keersmaecker
HWHans-Guido Wendel
Hans-Guido Wendel

14 September 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RRRamona Rudalska
Ramona Rudalska
DDDaniel Dauch
Daniel Dauch
TLThomas Longerich
Thomas Longerich
KMKatherine McJunkin
Katherine McJunkin
TWTorsten Wuestefeld
Torsten Wuestefeld
LZLars Zender
Lars Zender

1 January 2011 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JZJohannes Zuber
Johannes Zuber
KMKatherine McJunkin
Katherine McJunkin
CFChristof Fellmann
Christof Fellmann
LDLukas E Dow
Lukas E Dow
MTMeredith J Taylor
Meredith J Taylor
SLScott W Lowe
Scott W Lowe

1 March 2011 in Molecular Cell
Verified
Journal Article
Closed access
CFChristof Fellmann
Christof Fellmann
JZJohannes Zuber
Johannes Zuber
KMKatherine McJunkin
Katherine McJunkin
KCKenneth Chang
Kenneth Chang
CMColin D. Malone
Colin D. Malone
SLScott W. Lowe
Scott W. Lowe

2 February 2012 in Nature Protocols
Verified
Journal Article
Open access
PDF file
LDLukas E Dow
Lukas E Dow
PPPrem K Premsrirut
Prem K Premsrirut
JZJohannes Zuber
Johannes Zuber
CFChristof Fellmann
Christof Fellmann
KMKatherine McJunkin
Katherine McJunkin
SLScott W Lowe
Scott W Lowe
RNA interference (RNAi) is an extremely effective tool for studying gene function in almost all metazoan and eukaryotic model systems. RNAi in mice, through the expression of short hairpin RNAs (shRNAs), offers something not easily achieved with traditional genetic approaches—inducible and reversible gene silencing. However, technical variability associated with the production of shRNA transgenic strains has so far limited their widespread use. Here we describe a pipeline for the generation of miR30-based shRNA transgenic mice that enables efficient and consistent targeting of doxycycline-regulated, fluorescence-linked shRNAs to the Col1a1 locus. Notably, the protocol details crucial steps in the design and testing of miR30-based shRNAs to maximize the potential for developing effective transgenic strains. In all, this 14-week procedure provides a fast and cost-effective way for any laboratory to investigate gene function in vivo in the mouse.